3223 Phoenixville Pike
Malvern, PA 19355
Ph: (610) 644-8990
Fax: (610) 644-8717
Katherine D. Crothall,
President & CEO
Product Line or Service
Company is developing an insulin infusion pump and an implantable optical glucose
sensor for insulin-dependent diabetics. The sensor will be a long-term implantable device
(5 years or longer), will make measurements on a quasi continuous basis (once every two
minutes), and will make a direct measurement of blood glucose as opposed to an inferred
measurement (of some other body fluid). Dates of market introduction of pump and glucose
sensor are mid-1999 and 2001, respectively. Ultimately, the Company plans to couple its
sensor and pump together to provide closed-loop control of blood sugar.
Kusal Das, Principal Engineer (Mechanical)
Ian Shipway, Principal (Electrical)
Mike Sullivan, Principal Engineer (Optical)
Technology/Proprietary Rights Pending
patents (3) on the glucose sensor. No patents filed on insulin infusion pump although the
company anticipates doing so. Scientific feasibility (in-vitro measurements) of sensor has
been established on 500 + patients.
Market Opportunities The company
believes the ultimate market size for the insulin infusion pump is $ 0.5 billion and for
the sensor is $ 1.2 billion. Current market size for pump is about $ 130 million. The
companys products can reduce or possibly eliminate both the acute and long-term
complications of diabetes. In United States, the complications of diabetes are responsible
for approximately 15 % of the total healthcare costs of the country.
Marketing/Sales and Distribution None
as of yet; however, the Company anticipates selling the pump through distributors and
independent representatives both domestically and internationally. The Company also plans
on hiring a network of independent nurses (per diem basis) to provide patient education
and training. The Company has not yet formulated a distribution plan for the sensor.
Competition In pump market, Minimed
($80M revenues) and Disetronics ($50M revenues). There is no implantable or
minimally-invasive/ non-invasive sensor on the market although there are many groups
attempting to develop such a sensor. The Animas device overcomes the signal-to-noise and
artifact limitations of transcutaneous optical sensors and the encapsulation tissue
limitations of implantable chemical/electro-chemical sensors.
Manufacturing The Company intends to
do assembly and final test of both sensor and pump in house. Components will be
manufactured by outside vendors in accordance with specifications.